Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
arcticnovartis
Sun, 10/27/2024 – 02:04
Read more about Novartis oral Fabhalta® (iptacopan) sustained clinicall…
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
arcticnovartis
Sun, 10/27/2024 – 02:04
Read more about Novartis oral Fabhalta® (iptacopan) sustained clinicall…
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
arcticnovartis
Sun, 10/27/2024 – 02:04
Read more about Novartis oral Fabhalta® (iptacopan) sustained clinicall…
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
arcticnovartis
Thu, 10/24/2024 – 07:19
Read more about Novartis ribociclib (Kisq…
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis
Fri, 10/18/2024 – 12:49
Read more about Novartis receives positive CHMP opinion for Kisqali® to help…
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis
Fri, 10/18/2024 – 12:49
Read more about Novartis receives positive CHMP opinion for Kisqali® to help…
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis
Fri, 10/18/2024 – 12:49
Read more about Novartis receives positive CHMP opinion for Kisqali® to help…
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
arcticnovartis
Wed, 09/18/2024 – 08:04
Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch…
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
arcticnovartis
Wed, 09/18/2024 – 08:04
Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch…
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
arcticnovartis
Tue, 09/17/2024 – 19:04
Read more about FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- ea…
